The Latest Breaking News from Novartis

Novartis (NVS) is trading at new all-time highs on Monday. Shares are up nearly 50% over the past 52 weeks. NVS maintains a 100% “Buy” technical opinion from Barchart. Novartis has benefitted in recent days from its CEO’s comments that the company will have essentially limited tariff exposure by mid-2026....

Silicon Valley and Wall Street are pouring billions into AI drug discovery in a high-stakes bet to “solve” disease.

Researchers are reporting two promising approaches to counteract malaria's growing drug resistance

Treatment could be ‘the biggest advance in malaria treatment for decades,’ expert says

Experts said they were "very excited" by the findings

Swiss pharmaceutical major Novartis AG (NYSE:NVS) reported third-quarter 2025 results on Tuesday, reaffirming its full-year guidance as strong sales from key growth drugs offset mounting generic competition in the U.S.

Avidity Biosciences, Inc. (NASDAQ:RNA) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG (NYSE:NVS), marking one of the largest biotech buyouts of the year.

Avidity Biosciences, Inc. (NASDAQ:RNA) shares are rocketing premarket on Monday. On Sunday, the company agreed to merge with Novartis AG (NYSE:NVS) in a deal valued at $12 billion on a fully diluted basis.

Novartis AG (NYSE:NVS) on Wednesday shared topline data from the Phase 3 REPLENISH trial of Cosentyx in patients with polymyalgia rheumatica.